完整後設資料紀錄
DC 欄位語言
dc.contributor.authorWang, Chi-Chihen_US
dc.contributor.authorTsai, Ming-Changen_US
dc.contributor.authorPeng, Cheng-Mingen_US
dc.contributor.authorLee, Hsiang-Linen_US
dc.contributor.authorChen, Hsuan-Yien_US
dc.contributor.authorYang, Tzu-Weien_US
dc.contributor.authorSung, Wen-Weien_US
dc.contributor.authorLin, Chun-Cheen_US
dc.date.accessioned2018-08-21T05:53:02Z-
dc.date.available2018-08-21T05:53:02Z-
dc.date.issued2017-12-01en_US
dc.identifier.issn0954-691Xen_US
dc.identifier.urihttp://dx.doi.org/10.1097/MEG.0000000000000969en_US
dc.identifier.urihttp://hdl.handle.net/11536/144192-
dc.description.abstractObjective Health expenditure is a marker associated with an advanced healthcare system, which contributes toward the good prognosis of patients. Mortality-to-incidence ratios (MIRs) are one of the predictors that reflect the prognosis of cancer patients. There remains some uncertainty on the correlation of MIRs of liver cancer with the health expenditure of countries. Methods We therefore analyzed the correlation of MIRs from the GLOBOCAN 2012 database with the WHO rankings and the total expenditures on health/gross domestic product from WHO by linear regression analyses. A total of 29 countries were selected in this study according to the data quality and the incidence number. Results The results showed high rates of incidence/mortality and MIRs in less developed regions (0.92 vs. 0.96 for more vs. less developed regions). Among the continents, Asia has the highest incidence/mortality in case number, crude rate, and age-standardized rate. In terms of the MIR, Northern America has the lowest MIR and Latin America and the Caribbean have the highest MIRs (0.82 and 1.04, respectively). Finally, favorable MIRs are associated significantly with good WHO ranking and high expenditures on gross domestic product (P = 0.048 and 0.025, respectively). Conclusion The MIR variation for liver cancer is thus found to be associated with the health expenditure and WHO ranking. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.en_US
dc.language.isoen_USen_US
dc.subjectexpenditureen_US
dc.subjectincidenceen_US
dc.subjectliver canceren_US
dc.subjectmortalityen_US
dc.subjectmortality-to-incidence ratioen_US
dc.titleFavorable liver cancer mortality-to-incidence ratios of countries with high health expenditureen_US
dc.typeArticleen_US
dc.identifier.doi10.1097/MEG.0000000000000969en_US
dc.identifier.journalEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGYen_US
dc.citation.volume29en_US
dc.citation.spage1397en_US
dc.citation.epage1401en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000417291300011en_US
顯示於類別:期刊論文